Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUHCF1)

• Drug Name: Fluoxymesterone Drug Info
• Synonyms: Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Myotonia congenita, autosomal dominant		Approved	[2]
Noonan syndrome		Approved	[2]
Hypogonadism, male		Investigative	[2]

• Therapeutic Class: Anabolic Agents
• Cross-matching ID:
  PubChem CID: 6446
  ChEBI ID: CHEBI:5120
  CAS Number: CAS 76-43-7
  TTD Drug ID: DMUHCF1
  INTEDE Drug ID: DR1767
  ACDINA Drug ID: D00284

Molecule-Related Drug Atlas

Drug(s) Targeting Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[6]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[7]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[8]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[9]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[10]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[11]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[12]
ARN-509	DMT81LZ	Acute myeloid leukaemia	2A60	Approved	[13]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[14]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[15]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[16]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[17]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[18]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[19]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[20]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[21]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[22]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[23]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[17]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[24]

Drug(s) Affected By 11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[25]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[26]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[27]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[27]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[28]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[29]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[30]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[31]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[32]
Oxymetholone	DMFXUT8	Aplastic anemia	3A70	Approved	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Agonist	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2861).
• [2] Fluoxymesterone FDA Label
• [3] An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
• [4] Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes. Biochem Pharmacol. 1987 Jan 15;36(2):237-43.
• [5] The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012 Apr;126(2):353-61.
• [6] Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
• [7] Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
• [10] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [11] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [12] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [15] Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
• [16] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [17] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [18] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [19] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [20] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [21] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [22] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [23] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [24] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [25] SGK1, a potential regulator of c-fms related breast cancer aggressiveness. Clin Exp Metastasis. 2004;21(6):477-83.
• [26] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [27] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [28] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [29] Species-specific differences in the inhibition of human and zebrafish 11beta-hydroxysteroid dehydrogenase 2 by thiram and organotins. Toxicology. 2012 Nov 15;301(1-3):72-8.
• [30] Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
• [31] Inhibition of 11-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. Biochem Pharmacol. 2017 Apr 15;130:93-103. doi: 10.1016/j.bcp.2017.01.010. Epub 2017 Jan 25.
• [32] cAMP/PKA/EGR1 signaling mediates the molecular mechanism of ethanol-induced inhibition of placental 11beta-HSD2 expression. Toxicol Appl Pharmacol. 2018 Aug 1;352:77-86.